C18/00107 ere is a pressing medical need to develop innovative therapeutic proaches that improve the outcome and survival of pancreatic cancer
proaches that improve the outcome and survival of pancreatic cancer
tients. The development of immunotherapies has represented a eakthrough that has revolutionized oncology treatments, but with little ect in pancreatic tumors since they are considered non-immunogenic mors or with a tolerogenic/ immunosuppressive tumor croenvironment (TME). Turning pancreatic tumors to immunotherapies. uld open new avenues making them candidates for immunotherapies. is can be achieved by integrating techniques from two Key Enabling echnologies (KETs), nanotechnology and photonics. anoparticles have shown preferential accumulation in tumor sites rough (i) the enhanced permeability and retention effect (EPR), and (ii) e receptor-mediated internalization when they are opportunely nctionalized with specific ligands. Moreover, nanoparticles can also be signed to penetrate into the tumor stroma, interact with both tumor ncreatic cancer cells and cells of the TME, and efficiently release their rgo at the targeted site allowing to achieve a particular therapeutic sponse. e propose the development of photoactivable nanoemulsions mposted by bioactive sphingolipids for a dual action aimed to increase e immunogenicity of pancreatic tumors by i) reverting the erogenic/immunosuppressive tumor microenvironment of pancreatic ncer by modulating the phenotype of tumor associated immune cells

	(e.g. tumor-associated macrophages), and ii) mediating the infiltration of T effector lymphocytes (Teff), to reset the immunogenicity of pancreatic tumors, and make them candidates for the development of combinatory therapies with checkpoint inhibitors and/or other immune therapies such as bispecific antibodies
Entidad Financiadora	Instituto de Salud Carlos III (ISCIII)
Convocatoria:	EURONANOMED III "EUROPEAN INNOVATIVE RESEARCH & TECHNOLOGICAL DEVELOPMENT PROJECTS IN NANOMEDICINE" ACCIONES COMPLEMENTARIAS DE PROGRAMACION CONJUNTA INTERNACIONAL – AES 2018.
Importe de la ayuda	169.702,50€
Fechas de ejecución del proyecto	01/01/2019 - 31/12/2021
	Estas ayudas están financiadas por el Instituto de Salud Carlos III y cofinanciadas por FEDER, Programa Operativo Crecimiento Inteligente 2014-2020 "Una manera de hacer Europa"





UNIÓN EUROPEA Fondo Europeo de Desarrollo Regional

"Una manera de hacer Europa"

Enlaces:	http://euronanomed.net/ http://euronanomed.net/wp-content/uploads/2019/04/2018-PANIPAC.pdf Linkedin: www.linkedin.com/PANIPAC-project Twitter: User: @PANIPACproject
----------	---